Novocure GmbHs Optune Gio
Novocure, GmbH · Decision date Sep 18, 2026
What did the FDA approve?
FDA approved supplement S045 to PMA P100034 for Novocure GmbH's Optune Gio on September 18, 2026. The decision covers a location change for sterilization at SorVan Radiation, Ltd., Kiryat Soreq, POB 214, Yavne, 8180000, Israel. The device is classified as a low electric field tumor treatment stimulator under product code NZK, in the neurology specialty.
This supplement is a manufacturing site notice, not a new approval of the whole system. The statement identifies the changed item as the sterilizer location and does not report clinical data, a new indication, or independent evidence of safety or effectiveness. The source does not specify which components or quantities are sterilized at the new site, nor the sterilization method.
FDA approval order statement
Approval for a manufacturing site located at SorVan Radiation, Ltd., Kiryat Soreq, POB 214, Yavne, 8180000, Israel for sterilization.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Sep 18, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100034/S045
- Regulatory pathway
- PMA supplement
- Applicant
- Novocure, GmbH
- Product code
- NZK
- Decision code
- APPR
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, low electric field, tumor treatment.
- Applicant
- Novocure, GmbH
- Product code
- NZK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100034 · Original PMA
NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
P100034/S045 received
Application receipt date recorded by FDA.
P100034/S046 · Related supplement
Optune HFE Transducer Arrays
P100034/S045 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Novocure, GmbH | PMA approval | Apr 8, 2011 | FDA | |
Optune HFE Transducer ArraysP100034/S046 | Novocure, GmbH | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P100034/S045
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
